KDC-MN-1335 – Kodiac biolabs

Our opinion on this compoundEstablished, active research

33/100

Preclinical-only fragment with troubled parent clinical record and limited differentiation in tissue repair space

Look, there’s a specific problem with TB-500 Fragment that gets obscured by the enthusiasm around the parent thymosin beta-4 story: this is not the compound that generated the landmark data, and the compound that did generate landmark data has a troubled clinical record.

Philp et al. (2003) is the foundational paper. They showed that the synthetic heptapeptide Ac-LKKTETQ, residues 17-23 of thymosin beta-4, promoted wound repair in db/db diabetic mice at efficacy comparable to the full 43-amino acid parent. That’s a real finding. The identification of the actin-binding domain as the sufficient pharmacophore was genuinely useful, and it set the stage for Bock-Marquette et al.’s 2004 Nature paper on cardioprotection. But that Nature study used full-length thymosin beta-4, not the fragment. The fragment borrowed reflected glory from a result it didn’t produce.

Mechanistically, it works through G-actin sequestration, modulating actin polymerization dynamics and promoting cell migration, endothelial tube formation, and keratinocyte mobilization. Downstream signaling goes through ILK activation, Akt phosphorylation, NF-kappaB suppression, and upregulation of matrix metalloproteinases. Thats a multi-target profile with real biological coherence. What we like is that it’s a smaller, more metabolically stable probe than the parent, and the N-terminal acetylation confers aminopeptidase resistance. As a tool for studying actin-dependent tissue repair signaling, its genuinely useful at the bench.

Here’s the thing, though. The clinical track record for the parent molecule is not encouraging. RegeneRx’s ARISE Phase 3 program for dry eye disease failed to meet co-primary endpoints. The Phase 2 had shown real signal (35 percent improvement in ocular discomfort, 59 percent reduction in corneal fluorescein staining), so the Phase 3 failure is a genuine setback for the entire thymosin beta-4 pharmacology story. And that’s the parent. The heptapeptide fragment has essentially zero human clinical data of its own. We’re two steps removed from human evidence that has already stumbled.

Differentiation is also a problem. In the tissue repair peptide space, BPC-157 occupies more of the researcher mindshare and has a deeper, if imperfect, preclinical literature across multiple labs. GHK-Cu covers the dermal and wound-healing angle from a different mechanism. The fragment’s main claim to uniqueness is its size and its identity as the minimal active pharmacophore, which is scientifically interesting but doesn’t make it best-in-class for any specific indication or model type.

For bench work, we think this has real but limited value: useful for dissecting which activities of TB-4 are actin-binding-domain dependent, and for probing the ILK/Akt axis in tissue repair models without the complexity of the full parent protein. But it’s not an indispensable probe. Solid preclinical foundation, coherent mechanism, a clinical record that should give anyone pause. The score reflects that honestly.

Novelty: 28
Mechanism promise: 42
In-category differentiation: 30
Evidence quality: 32
Translational signal: 25
Research bench value: 45

Rationale The heptapeptide fragment has real multi-lab preclinical support and a coherent multi-target mechanism, but clinical evidence derives entirely from the full-length parent molecule, which failed Phase 3 primary endpoints in ARISE; the fragment itself has no human data, and differentiation against BPC-157 and GHK-Cu in the tissue repair space is weak.

Heptapeptide active fragment of thymosin beta-4

A seven-residue actin-binding fragment of thymosin beta-4 (Tβ4 residues 17 through 23), studied as the minimal active region driving the cell migration and angiogenic effects of the parent peptide.

Abstract

TB-500 Fragment (Leu-Lys-Lys-Thr-Glu-Thr-Gln; LKKTETQ; thymosin beta-4 residues 17 through 23; molecular weight 819.93) is a seven-residue synthetic peptide corresponding to the minimal actin-binding region of thymosin beta-4 (Tbeta4), the 43-residue actin-sequestering protein expressed at high concentration in platelets, leukocytes, and many other cell types. The full-length Tbeta4 sequence is the molecule supplied as Kodiac biolabs TB-500 (KDC-MN-003); the LKKTETQ fragment is a separate research-grade preparation that has been used in vendor literature and a limited research literature interchangeably with TB-500 (a confusion that should be resolved by mass spectrometry on each lot, since the fragment and full-length peptides have very different masses). The pharmacological argument for the heptapeptide is that LKKTETQ retains the cell migration and angiogenic activity of the parent at substantially lower molecular weight, with potentially favorable pharmacokinetic and tissue distribution profiles. Published in vitro and rodent studies support migration-promoting activity at this minimal sequence. The full-length Tbeta4 has additional activities (anti-inflammatory effects, regulation of cardiac and corneal repair) that depend on residues outside the 17-23 region and are not necessarily reproduced by the fragment. Investigators should specify whether the research-grade preparation in question is the full-length 43-residue peptide (KDC-MN-003) or the LKKTETQ heptapeptide (this monograph), since the published preclinical record is dominated by the full-length compound and translation of full-length results to fragment dosing should be done with caution. Reconstitution and handling parallel other small synthetic peptides; the heptapeptide is highly water-soluble and stable to lyophilization. Plasma half-life is on the order of minutes; tissue retention is shorter than for the full-length peptide.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1335Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1335

TB-500 Fragment (LKKTETQ)

Abstract

Read the full monograph